GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Cyclically Adjusted Price-to-FCF

LadRx (STU:CX5) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


LadRx Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for LadRx's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Cyclically Adjusted Price-to-FCF Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LadRx's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, LadRx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where LadRx's Cyclically Adjusted Price-to-FCF falls into.



LadRx Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

LadRx's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, LadRx's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.598/129.4194*129.4194
=-1.598

Current CPI (Dec. 2023) = 129.4194.

LadRx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -53.796 99.695 -69.836
201406 -80.280 100.560 -103.320
201409 -102.559 100.428 -132.166
201412 -106.022 99.070 -138.502
201503 -126.043 99.621 -163.745
201506 -108.441 100.684 -139.390
201509 -87.453 100.392 -112.740
201512 -111.694 99.792 -144.854
201603 -107.838 100.470 -138.910
201606 -101.491 101.688 -129.169
201609 -89.961 101.861 -114.300
201612 -54.139 101.863 -68.785
201703 -41.265 102.862 -51.919
201706 -30.444 103.349 -38.124
201709 -11.722 104.136 -14.568
201712 -22.336 104.011 -27.792
201803 -4.588 105.290 -5.639
201806 -11.079 106.317 -13.486
201809 -5.567 106.507 -6.765
201812 -8.634 105.998 -10.542
201903 -4.247 107.251 -5.125
201906 -2.404 108.070 -2.879
201909 -2.361 108.329 -2.821
201912 -6.378 108.420 -7.613
202003 -2.251 108.902 -2.675
202006 -1.884 108.767 -2.242
202009 -4.881 109.815 -5.752
202012 -5.868 109.897 -6.910
202103 -1.567 111.754 -1.815
202106 -2.197 114.631 -2.480
202109 -2.545 115.734 -2.846
202112 -21.524 117.630 -23.681
202203 -3.459 121.301 -3.691
202206 -1.630 125.017 -1.687
202209 -2.271 125.227 -2.347
202212 -2.870 125.222 -2.966
202303 -1.419 127.348 -1.442
202306 6.141 128.729 6.174
202309 -1.269 129.860 -1.265
202312 -1.598 129.419 -1.598

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LadRx  (STU:CX5) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


LadRx Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of LadRx's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (STU:CX5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines